Your eight-year-old daughter is sitting on your front steps right now in the freezing cold, my neighbor Brenda whispered over the phone at 12:14 AM. "Her clothes are covered in wet blood, Mark. S...
I left the hospital through the basement service exit before security noticed my presence. The cold concrete walls felt appropriate, a reflection of the hard truth I was uncovering. I drove back to David’s house, my mind racing through every detail of Sarah’s final months, the image of her gaunt face in Ward 4B flashing in my memory.
I pulled up my laptop in David’s kitchen and opened my personal financial records from Sarah’s illness. I had saved every paper bill, every insurance explanation of benefits, and every pharmacy printout from her stay in Ward 4B. They were a painful archive, but now they felt critical.
I spread the paper sheets across the kitchen table, the crinkle of the old documents loud in the quiet room.
“What are you looking for?” David asked, sitting down with two cups of dark coffee, pushing one toward me. He looked at the scattered papers with a somber expression.
“The drug name,” I said, my fingers trembling slightly as I flipped through Sarah’s final discharge summary. “When Sarah died, the doctors told me her liver collapsed due to late-stage leukemia complications. They said it was aggressive, unavoidable.”
I paused, pointing to a line item. “But three days before she passed, Evelyn personally transferred her from her palliative care program to Protocol 409-A. She told me it was a ‘new, experimental palliative treatment’ to make her more comfortable.”
I found the billing code: *compound PX-409.* The name was branded into my memory from endless insurance appeals.
I then looked at the legal affidavit served to me that morning by Evelyn’s process server. Under Dr. Ellison’s signature, the pediatric trial designation was clearly printed: *Protocol 409-B Pediatric Extension.* The compound listed was identical.
“It’s the same compound,” I whispered, staring at the paper, a cold fury building in my chest. “They gave Sarah the adult formulation. It failed. It killed her, David.”
My voice cracked. “Now they’re using Maya to validate the pediatric phase before the federal grant window closes tonight. They need her genetic markers to prove the drug isn’t universally toxic.”
“Why would Evelyn risk her own grand-niece for a research grant?” David asked, his voice horrified, pushing his coffee mug away as if the very thought sickened him.
“Because if Protocol 409 fails its grant audit, St. Jude has to return the two point five million dollars to the Abernathy foundation,” I said, the words coming out in a rush. “And as senior administrative trustee, Evelyn personally managed those foundation funds. She funneled hundreds of thousands into ‘administrative overhead.’ If the money comes back empty, an audit will show where the administrative overhead fees went. It would expose her financial mismanagement.”
More Stories
+ There are no comments
Add yours